ArticleDer Urologe. Ausg. A2015
[Cryoablation of prostate cancer].
Article in Der Urologe. Ausg. A, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to continuous technical developments for more than 60 years followed by better clinical results with minimal side effects, cryoablation of the prostate for localized prostate cancer has evolved as a true alternative therapeutic option for selected patients. THEMATA: The current form of cryoablation has almost nothing in common with those established in the 1960s and 1970s, which were further developed in the 1980s and 1990s. Nowadays it is a minimally invasively and highly effective treatment for high-risk carcinomas and failure of other therapeutic modalities.
conclusionThus, cryoablation of the prostate is indicated if there are absolute or relative contraindications for radical surgery. In salvage cases for localized prostate cancer, cryoablation is the therapy of choice. Cryoablation is also an option for focal therapy. Standardization of the procedure, definition of freeze-thaw cycles, and structured training programs have led to this status.
Indexed as
Identifiers
25659982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.